Positive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer Research
Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) announced today that positive data from the investigator-initiated study evaluating the effects of remetinostat in basal cell carcinoma (BCC) patients has been published in Clinical Cancer Research (online first doi: 10.1158/1078-0432.CCR-21-0560). This clinical study was conducted at the Stanford University School of Medicine in California, USA under the leadership of the principal investigator, Dr Kavita Sarin. Results of the open-label clinical trial of the topical HDAC inhibitor, remetinostat, as neoadjuvant treatment for BCC were